Insmed (INSM) stock led a biotech rally Thursday, catapulting 30% on solid second-quarter sales for its new lung disease drug, Brinsupri. First, Brinsupri ā a treatment for non-cystic fibrosis bronchiectasis ā walloped sales expectations, generating $309.2 million vs. forecasts for $276.6 million, according to FactSet. Then, Insmed raised its guidance for the drug this year…
IBD 50 stock Exelixis (EXEL) toppled early Thursday on a mixed second-quarter report, as sales of its bread-and-butter cancer drug, cabozantinib, lagged expectations. The biotech company sells cabozantinib under the brand names Cabometyx and Cometriq. The former ā a treatment for kidney, liver and thyroid cancers as well as neuroendocrine tumors ā brought in $570.6…
Moderna (MRNA) stock wavered and slumped Thursday after the Food and Drug Administration approved its mRNA-based flu shot, now called mFlusiva. The approval comes after a lengthy battle with former FDA authorities. Previously, the FDA refused to review Moderna’s application, saying the study wasn’t “adequate or well controlled” and the standard flu shot it used…
Ligand stock settled back into a profit-taking zone Thursday on a strong second-quarter report thanks to its ties to drugs from Merck (MRK), Travere Therapeutics (TVTX) and Pelthos Therapeutics (PTHS). The company doesn’t make drugs. Instead, Ligand Pharmaceuticals (LGND) funds the development of what it hopes are the market’s next winners. In return, it receives…
John Eade President & Director of Portfolio Strategies John is chairman and CEO of Argus Research Group and president of Argus Research Company. Over the years, his responsibilities at Argus have included chairing the Investment Policy Committee as then director of research; helping form the firm’s overall investment strategy; writing a weekly investment column; and…
Instructions: Entry point: yellowStop loss: redTake profit: green šLeverage x 5-10-20 for cryptošLeverage x 20-50-100 for commodities, stocks, indices, and forexšMargin 1-5% max.Always practice risk and money management.Invest a maximum of 5% on any trade or across all your trades.Invest only what you can afford to lose, as no one is in control of the…
Instructions: Entry point: yellowStop loss: redTake profit: green šLeverage x 5-10-20 for cryptošLeverage x 20-50-100 for commodities, stocks, indices, and forexšMargin 1-5% max.Always practice risk and money management.Invest a maximum of 5% on any trade or across all your trades.Invest only what you can afford to lose, as no one is in control of the…
Hey Everyone, A question many traders have been asking is why Gold failed to rally during the recent escalation in tensions between President Trump and Iran. Traditionally, geopolitical uncertainty creates safe haven demand, which can support Gold. However, this does not mean every war headline will automatically send the market higher. The reaction depends on…
Instructions: Entry point: yellowStop loss: redTake profit: green šLeverage x 5-10-20 for cryptošLeverage x 20-50-100 for commodities, stocks, indices, and forexšMargin 1-5% max.Always practice risk and money management.Invest a maximum of 5% on any trade or across all your trades.Invest only what you can afford to lose, as no one is in control of the…
Trade Setup & Parameters Bias: Long Entry Price: 158.204 (Breakout & retest of key resistance zone) Stop Loss: 157.518 (Below intermediate swing low) Take Profit: 160.778 (Major high / liquidity target) Risk/Reward Ratio: ~3.7:1 Technical Breakdown Structural Shift: Following the completion of the 5-wave impulsive decline down to the support zone near 155.30, price initiated…
End of content
End of content